Tag: Gilead Sciences

Gilead’s HIV treatment obtained EU marketing authorization

hiv
Gilead Sciences announced that the European Commission has granted Marketing Authorization for Biktarvy®, a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.

Gilead and Hookipa Biotech will develop HIV and Hepatitis B treatments

gilead sciences
Hookipa Biotech AG, an Austrian clinical-stage biotech company, and Gilead Sciences, a research-based biopharmaceutical company, entered into a research collaboration and license agreement.

Kite obtains new R&D facilities to develop cell therapies

cancer treatment
The new site in Hoofddorp will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020.

Gilead Sciences and Verily Life Sciences start a scientific collaboration

gilead
Gilead Sciences and Verily Life Sciences announced a scientific collaboration using Verily’s platform to identify and better understand the immunological basis of three common and serious inflammatory diseases.

Gilead and Sangamo joined up for development of next gen cell therapies

gene-editing
Kite, a Gilead Company, and Sangamo Therapeutics entered into a worldwide collaboration using Sangamo’s zinc finger nuclease (ZFN) technology platform for the development of next-generation ex vivo cell therapies in oncology.

GSK brings legal action against Gilead Sciences

gsk
ViiV Healthcare, the global specialist HIV company majority-owned by GlaxoSmithKline with Pfizer Inc. and Shionogi Ltd., announced that it has filed patent infringement litigation against Gilead Sciences

Gilead starts a new clinical collaboration with Pfizer

gilead
Kite, a Gilead Company, announced a clinical trial collaboration with Pfizer to evaluate the safety and efficacy of the investigational combination of Yescarta and Pfizer's utomilumab

Gilead Sciences buys Cell Design Labs

gilead
Gilead Sciences and its subsidiary Kite announced that they have entered into a definitive agreement under which they have agreed to acquire Cell Design Labs

Gilead Sciences completed the purchase of Kite Pharma

gilead
Gilead Sciences, Inc. announced the completion of the previously announced transaction for a subsidiary of Gilead to acquire Kite Pharma

Gilead Sciences will pay $11.9 million for Kite Pharma

gilead
Gilead Sciences, Inc. and Kite Pharma, Inc. announced today that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Kite for $180.00 per share in cash

Contract manufacturing

TOP NEWS

POPULAR ARTICLES

Рейтинг@Mail.ru
© GMP news